Genitourinary Cancer

Several key abstracts presented at the 2019 ASCO Annual Meeting demonstrated practice-changing potential in the prostate cancer field, said Celestia S. Higano, MD, FACP.

A pediatric oncology nurse’s experience came full circle following her own bladder cancer diagnosis, followed by serving as a caregiver to her husband who faced the same disease 6 years later.

Liquid biopsies and other novel techniques have the potential to change the bladder cancer space. However, unanswered questions remain.

Switch maintenance treatment with pembrolizumab (Keytruda) improved progression-free survival (PFS) in patients with metastatic urothelial cancer who have stable disease following frontline platinum-based chemotherapy, according to results of a randomized phase II study that were presented at the 2019 ASCO Annual Meeting.

The Food and Drug Administration approved bevacizumab-bvzr (Zirabev) – a biosimilar for bevacizumab (Avastin) for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

Healthcare providers should not base cancer care with immune checkpoint inhibitors on gender, according to recent study findings.

There may be a correlation between androgen deprivation therapy and cardiac complications, but more research is still needed.

Nurses now have a wealth of new and updated resources to ensure their patients with prostate cancer can make the best treatment choices they can, thanks to the Prostate Cancer

Two new urine tests currently being investigated for bladder cancer detection and monitoring have demonstrated more than 90% sensitivity and specificity – highlighting the potential for addressing an unmet need among this patient population.

The FDA approved the combination use of avelumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma.

When it comes to the treatment of patients with nonmetastatic castration-resistant prostate cancer (M0CRPC), 3 pivotal trials—SPARTAN, PROSPER, and most recently, ARAMIS—have demonstrated the safety and efficacy of second-generation targeted antiandrogens, said Richard (Rick) JaeBong Lee, MD, PhD.

After the USPSTF advised against prostate cancer screening for all men, there was a decrease in the incidence of the disease.

The FDA has granted a priority review designation to a new drug application (NDA) for darolutamide for use as a treatment for patients with nonmetastatic castration-resistant prostate cancer (CRPC).

The FDA has approved pembrolizumab (Keytruda) in combination with axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).

Nurses can help manage post-traumatic stress disorder symptoms in survivors of non-muscle invasive bladder cancer.

The FDA granted an accelerated approval for erdafitinib to treat patients with metastatic or locally advanced bladder cancer that harbors certain genetic mutations.

Radiation's role continues to shift in the treatment of patients with prostate cancer.

Emmanuel S. Antonarakis, MBBCh, an associate professor of oncology at Johns Hopkins Medicine, discussed updated National Comprehensive Cancer Network (NCCN) guidelines for the genetic testing of men with prostate cancer.

While there are some exciting advances coming down the pipeline, there is still much work to do when it comes to the molecular diagnosis of patients with renal cell carcinoma (RCC), explained David I. Quinn, MBBS, PhD, FRACP, FACP.

PD-L1 status may not be the best predictor when it comes to determining who will respond to checkpoint blockade.

Communicating with men about bone health and osteoporosis can pose quite a challenge as this is something many men have often associated with women’s health.

Genetic mutations that were previously associated with breast and ovarian cancer also have implications for men with prostate cancer.

The FDA granted a priority review to pembrolizumab (Keytruda) in combination with axitinib (Inlyta) as a frontline treatment for advanced renal cell carcinoma.

The FDA granted a priority review to avelumab (Bavencio) in combination with axitinib (Inlyta) to treat patients with advanced renal cell carcinoma (RCC).